Exciting new Part the Cloud updates

Exciting new Part the Cloud updates

Part the Cloud has raised $65 million since 2012

Since its inception in 2012, Part the Cloud has raised more than $65 million accelerating 60 high risk, high reward research projects thanks to our generous supporters and community. Part the Cloud researchers have gone on to receive more than $940 million in follow-on funding.

Promising results of a Part the Cloud-funded study move adult cell therapies forward

A recent paper published in Alzheimer's & Dementia®: The Journal of the Alzheimer’s Association shared promising results from a Phase I clinical trial of Lomecel-B for Alzheimer’s disease (AD). Lomecel-B contains a special type of cell derived from young healthy adults, called medicinal signaling cells (MSCs), that the study supported was safe to administer to individuals with mild AD.  Disease-related changes were also measured in those receiving treatment compared to those who did not receive the treatment; however, the small sample size required of the phase 1 safety trial necessitates confirmation of these early results in larger next-step trials. The study team is now advancing this program to investigate the clinical potential of Lomecel-B in a larger population, and a Phase II trial is currently underway.

Authors include individuals from Part the Cloud awardee Longeveron Inc., including co-founder Joshua Hare, Anthony Oliva, Jr. (senior author), Kevin Ramdas and Lisa Mcclain-Moss. Read the full research publication here.

Part the Cloud updates from American Academy of Neurology (AAN) meeting

Nine Part the Cloud-funded researchers shared research at AAN, including:

Part the Cloud is a movement to transform progress in Alzheimer's research by investing in researchers that are advancing the field and providing valuable contributions to advance potential preventions, diagnosis and therapies.

Part the Cloud researchers highlighted at global AD/PD conference

Last month, the AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders took place in Barcelona, Spain. Approximately 3,000 scientists and clinicians from around the world attend AD/PD (2,000 in-person and 1,300 virtual), which has historically only been held in the EU.

AD/PD provides an intimate setting for researchers to present their work and collaborate with other scientists. Most of these experts and leaders have been supported by the Alzheimer’s Association through grant funding and ISTAART leadership opportunities. Part the Cloud awardee Miia Kivipelto, M.D., Ph.D., presented her findings about resilience and vulnerability factors, risk assessment, prevention and clinical trials, and Frank Longo M.D., Ph.D., and Roberta Brinton, Ph.D., reported on recent progress of their research into specific therapeutic targets. Both research teams are working on the next phase of their clinical trials - Phase II for Dr. Brinton and Phase III for Dr. Longo. As previously mentioned, Charbel Moussa, M.D., Ph.D., whose Part the Cloud grant allows him to explore repurposing an FDA-approved leukemia drug, also shared his findings at AD/PD.  Part the Cloud was instrumental in moving these potential treatments through this pipeline.

“The funding (from Part the Cloud) has made it possible to run the first multimodal precision prevention trial combining lifestyle and drug interventions for dementia prevention.”

            -Miia Kivipelto, M.D., Ph.D.

In the news

On April 7, Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab (brand name Aduhelm™) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer’s disease.

"The decision by CMS is a step backward for families facing Alzheimer's disease," said Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer. "Years of increased research funding has led to more progress and innovation than ever before, but today's decision may halt this progress as developers question if there is a pathway forward to coverage."

Read the Alzheimer’s Association statement


To fund Alzheimer's research with the highest probability of slowing, stopping or ultimately curing Alzheimer's disease.